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Abstract: B lymphocyte receptors are generated randomly during the bone marrow 
developmental phase of B cells. Hence, the B cell repertoire consists of both self and 
foreign antigen specificities necessitating specific tolerance mechanisms to eliminate self-
reactive B cells. This review summarizes the major mechanisms of B cell tolerance, which 
include clonal deletion, anergy and receptor editing. In the bone marrow presentation of 
antigen in membrane bound form is more effective than soluble form and the role of 
dendritic cells in this process is discussed. Toll like receptor derived signals affect 
activation of B cells by certain ligands such as nucleic acids and have been shown to play 
crucial roles in the development of autoimmunity in several animal models. In the 
periphery availability of BAFF, a B cell survival factor plays a critical role in the survival 
of self-reactive B cells. Antibodies against BAFF have been found to be effective 
therapeutic agents in lupus like autoimmune diseases. Recent developments are targeting 
anergy to control the growth of chronic lymphocytic leukemia cells. 
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1. Introduction  
The development of an adaptive immune system requires generation of antibody receptors with 
varied affinities some of which will have reactivity to self-antigens. In the B-cell lineage, self-reactive 
B cells are eliminated in the bone marrow (Central tolerance) and the spleen (Peripheral tolerance). By 
utilizing a variety of transgenic mouse models, researchers have demonstrated that the central 
tolerance mechanisms exclude autoreactive immature B cells and prevent cells that exhibit self-
reactive B-cell receptors from entry into the peripheral B-cell compartment. Additional studies have 
revealed mechanisms that promote the differentiation of non-autoreactive immature B cells and their 
positive selection into the peripheral B-cell compartment. These central tolerance mechanisms are 
fundamental to the generation of a naive B-cell repertoire that is largely devoid of self-reactivity while 
capable of reacting with any foreign antigen. 
B-cells are generated in the bone marrow in a tightly regulated manner. Productive rearrangement 
of immunoglobulin heavy (IgH) and light (IgL) chain gene segments results in the generation and 
expression of the mature B-cell antigen receptor (BCR) at the cell surface. While specific combination 
of Ig H and L chains determines the antigenic specificity of the newly formed BCR, its association 
with Ig-α and Ig-β allows transduction of a signal inside the cell that directs cell fate [1,2]. Developing 
B cells first express a mature BCR on the cell surface in the form of IgM and as such are classified as 
immature B cells (Figure 1) [3–5]. It is at the immature B-cell stage that the BCR is exposed to 
autoantigens in the bone marrow. Central B-cell tolerance is the process that negatively selects newly 
generated immature B cells that react with a self-antigen in the bone marrow environment. This is 
considered the first checkpoint of B-cell tolerance, and the outcome of this checkpoint mechanism is 
fundamental to the generation of a naive B cell repertoire that contains BCRs reactive to foreign 
antigens and is mostly devoid of self-reactive specificities. Once the central checkpoint is successfully 
overcome, immature B cells differentiate into transitional and mature B cells in the spleen [4,6,7]. 
However, a fraction of autoreactive immature B cells, that retains low reactivity to self-antigens, 
escapes the central checkpoint of tolerance and migrates into the periphery [6–8]. 
2. Central Tolerance: Clonal Deletion, Anergy and Receptor Editing 
Burnet’s clonal selection theory suggested that lymphocyte clones that react to self are eliminated to 
prevent immune responses against self-antigens [9]. Seminal work from many investigators involved 
injecting antibodies reactive toward immunoglobulin (Ig) chains into newborn mice and rabbits to test 
whether newly generated B cells reacted with a “self-antigen,” (in this case, the rabbit anti-Ig antibody 
acts like a self-antigen), would either be deleted or modulated [10–17]. Consistent with such a 
hypothesis, injection of anti-Ig antibody and anti-idiotypic antibodies in newborn animals resulted in 
the elimination of Ig and idiotype-expressing B cells, respectively. Later on, with the advancement of 
transgenic mice technology, anti-hen egg lysozyme (HEL) and anti-H-2Kk (and H-2Kb) Ig transgenic 
mice were developed with the purpose of testing whether newly generated autoreactive B cells were 
either eliminated or suppressed on recognition of their specific self-antigen. These studies indicated 
that when an immature B cell reacts with a self-antigen with high avidity, such as a highly expressed 
membrane-bound protein, it undergoes apoptosis within 2–3 d [3,18]. In contrast, low avidity 
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interactions of B cells with self-antigens induce unresponsiveness to subsequent stimulation or anergy 
but allowed for migration into peripheral compartment. The anergic B cells fail to enter follicle and 
have reduced life-span [3]. Therefore, it was concluded that clonal deletion and anergy were major 
mechanisms mediating central tolerance of developing autoreactive B cells, resulting in the elimination 
of autoreactive clones, and preventing immune responses against self. However, later studies showed 
that clonal deletion and anergy are not the only modes of selection against autoreactive immature B 
cells, but there operates another system, namely, receptor editing. Several important studies that 
utilized immunoglobulin heavy and/or light chain transgenic mouse models in which the self-antigens 
were either MHC class I or DNA showed that autoreactive immature B cells “edit” their antigen 
receptors [19,20]. Specifically, autoreactive immature B cells reactivated their Ig gene rearrangement 
program at the Ig light chain loci resulting in the expression of a new light chain that paired with the 
existing H chain to form a non-autoreactive BCR, an event that promoted the selection of these edited 
B cells into the periphery. The concept of “receptor editing” was thus born. Several studies with 
human B cells have shown that receptor editing also plays a role in shaping human B cell repertoire 
and failures in regulation of these mechanisms are involved in lupus like autoimmune diseases [21]. 
Despite a critical role for BCR affinity in deciding the fate of immature B cells, their selection is also 
influenced by the bone marrow microenvironment [2]. 
3. Peripheral Tolerance – Role of BAFF (BLyS) 
The central tolerance mechanisms eliminate approximately 90% of the self-reactive B cell  
pool [5,22]. Despite the presence of clonal deletion, anergy and receptor editing mechanisms, several 
autoreactive clones bypass these checkpoints and are found in peripheral B cell pool [8,23,24]. 
Immature B cells that survived the central tolerance leave the bone marrow and continue their 
development as transitional B cells in the periphery. Here they undergo peripheral tolerance based on 
their BCR specificity and signal strength. The BCR signal strength must fall within the range for 
further maturation and selection: above the “tonic” signaling for positive selection and below the 
threshold signaling for negative selection [2,25,26]. The “transitional B cell tolerance” is the first B cell 
tolerance check point in the periphery, which eliminates about two-thirds of the transitional B cells [5]. 
Unlike the central tolerance mechanisms, the stringency of transitional B-cell tolerance is plastic and 
selection depends on the interplay between BCR-mediated signals and a B cell survival factor, called B 
lymphocyte stimulator (BAFF, also known as BLyS) signaling [27]. 
BAFF is a soluble type II transmembrane protein that promotes key biological functions including 
peripheral B-cell survival and homeostasis [28]. In addition to promoting B-cell survival, BAFF also 
regulates expression of CD21/35 on the surface of B cells [27,29]. BAFF deficiency results in a 
reduction in the number of peripheral B cells and a diminished capacity to mount robust humoral 
immune responses. Overexpression of BAFF has been linked to human autoimmunity, and recent data 
provide clues as to how excessive secretion of BAFF may allow the emergence of autoreactive B cells 
in mice and humans [28,29]. BAFF binds to three receptors: BAFF receptor 3 (BR3; also known as 
BAFF-R), transmembrane activator-1 and calcium modulator and cyclophilin ligand-interactor 
(TACI), and B cell maturation antigen (BCMA). BAFF-R is one of the BAFF receptors expressed on 
all peripheral blood B cells in both mice and humans. In the mouse spleen, BAFF-R is most highly 
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expressed on transitional type 2 (T2) B cells, followed by mature and marginal zone (MZ) B cells, 
while T1 cells having lower levels of BAFF-R on the surface, and GC B cells have reduced expression 
compared to mature follicular B cells. Human tonsillar B cells have a high level of BAFF-R 
expression, and like mouse, tonsillar B cells with a GC phenotype express BAFF-R in reduced  
levels [30–32]. It was shown that BAFF-R is not expressed on B-cell precursors in the bone marrow. 
BAFF-R was initially believed to be expressed exclusively by B cells; however, BAFF-R was recently 
found to be expressed on a subset of mouse splenic T cells and on human anti-CD3-activated 
peripheral blood T cells [33–36]. Close examination of tonsillar T cells revealed that a large proportion 
of effector and memory T cells express BAFF-R, while naive T cells are negative [31,32].  Although 
mRNA for BCMA, another receptor for BAFF can be found in the spleen, lymph nodes, and several  
B-lineage cell lines, cell-surface BCMA is undetectable. TACI, a third receptor for BAFF was found to 
be expressed on B cells and a subset of activated T cells [31,32]. In the mouse, splenic MZ and T2 B 
cells have the highest level of TACI expression, while expression on T1 and mature B cells is low or 
absent. In the absence of BAFF, B cell development remains normal in the bone marrow, but 
peripheral B cells are reduced significantly. BAFF signaling is crucial for the survival of late 
transitional (T2 and T3), follicular and marginal zone B cells, whereas B-1 B cells remain unaffected 
due to lack of BAFF [37,38]. 
Elevated levels of BAFF lead to defect in transitional B cell tolerance and a breach in the peripheral 
tolerance. Studies with the immunoglobulin knock-in mice that express self-reactive BCRs show that 
most of the transitional B cells are negatively selected during transitional B cell tolerance. However, 
administration of exogenous BAFF in these mice results in an increase in number of self-reactive B 
cells in the mature B cell pool [39,40]. Thus, B cells that would normally be deleted through negative 
selection instead survive because of BAFF signaling and join the mature naïve B-cell pool. These 
studies suggest that BAFF is a limiting factor in transitional B-cell tolerance. Increased levels of BAFF 
lowered the BCR affinity threshold required for positive selection with a consequence that  
self-reactive B cells with a low affinity BCR were rescued into the peripheral repertoire. Consistent 
with this idea, aberrant transitional tolerance processes because of elevated levels of BAFF have been 
identified in patients with antibody mediated autoimmune diseases [41–44]. These observations made 
BAFF an attractive therapeutic target, and subsequently a BAFF-blocking monoclonal antibody, 
Belimumab (Benlysta), received FDA approval in 2011 as a treatment for patients with systemic lupus 
erythematosus (SLE) [45,46]. Treatment with Belimumab leads to a significant reduction in autoantibodies 
and selected B cell subsets (naïve, transitional but not memory B cells) in SLE patients [47]. Though 
Belimumab has promising potential, it does have reduced benefits in long term clinical care of 
patients. Clinical trials comparing two doses of Belimumab (1 or 10 mg/kg), were performed in adult 
patients (n = 1684). It was shown that after 52 weeks patients who responded to the drug were about 
10% higher with belimumab (10 mg/kg) than with placebo. However, this response was not observed 
in one of the trials at 76 weeks [48]. Although it was demonstrated that treating patients with 
Belimumab provided no statistically significant therapeutic benefit, the positive outcome of these two 
trials is that patients with highly active disease had clinical benefit. Belimumab has been shown to be 
immunosuppressive and to exacerbate the effects when combined with other immunosuppressive  
drugs [48–50]. Different mechanisms of B cell tolerance in bone marrow and periphery are 
summarized in Figure 1. 
Antibodies 2014, 3 120 
 
Figure 1. Mechanisms of B-cell tolerance in bone marrow and periphery: Both clonal 
deletion and anergy are mechanisms utilized in the primary as well as peripheral lymphoid 
organs. Strength of BCR signaling affects the fate of the B cells undergoing tolerance. 
Receptor editing occurs primarily in the bone marrow. Transitional B cells are found in the 
bone marrow and spleen. Peripheral tolerance is primarily found in splenic transitional B 
cells, which depends on tonic BCR signaling thresholds and survival signals from BAFF. 
 
4. Peripheral Tolerance - Role of Toll-Like Receptors  
Toll-like receptors (TLRs) are pattern recognition receptors that recognize pathogen associated 
molecular patterns (PAMPs) [51,52]. TLR-mediated recognition of PAMPS leads to activation of 
innate immune cells [53]. TLR signaling promotes activation and maturation of innate immune cells, 
which instructs and supports T-cell activation, leading to cell-mediated adaptive immune response. 
Activated antigen-specific T cells and naïve B cells interact with each other (cognate interaction), 
which leads to B-cell clonal expansion and differentiation and antibody secretion. Recent evidence 
suggests that in addition to TLR signaling in cells of the innate immune system, direct TLR mediated 
activation of B cells is also required for eliciting humoral immune response. However, multiple B cell 
subsets exists that play distinct roles during humoral immune responses. For example, follicular B cells 
are shown to be important for T-dependent immune responses whereas marginal zone B cells are 
important for T-independent immune responses. Marginal zone B cells are shown to be in a pre-
activated state and respond rapidly to LPS and secrete antibody in vitro. Peyer’s patch B cells in the 
intestine play critical role in mucosal immune response by secreting IgA that binds to pathogens and 
prevents enteric infections. B-1 B cells, a subset of B cells in the peritoneal cavity is the source of 
natural IgM present in the serum and plays an important role in immunity against blood borne 
pathogens [6,54]. It was shown that B-cell subsets express all known TLRs except 5 and 8 [55]. 
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In a series of landmark studies, it was demonstrated that TLRs expressed by B cells can also 
recognize self-antigens released from host tissues that are damaged, and such self-recognition by the B 
cell intrinsic TLR can potentially promote the development of autoimmune disease by breaking B-cell 
tolerance. Studies from transgenic mice reveal that immune complexes (ICs) consisting of IgG bound 
to mammalian DNA have been shown to effectively activate transgenic rheumatoid factor (RF) 
specific B cells through a process that involves BCR recognition of the IC and subsequent delivery of 
the DNA to TLR9 sequestered in an endosomal/lysosomal compartment [56–58]. These low affinity 
RF specific B cells do not proliferate in response to protein-containing ICs. The chromatin ICs, but not 
protein ICs, stimulate myeloid and plasmacytoid DCs to secrete cytokines, through coengagement of 
both FcγRs and TLR9. Under specific conditions, mammalian DNA can also directly stimulate DNA-
reactive cells, through a TLR9-dependent process. However, the role of TLR9 in lupus appears more 
complex since deletion of Tlr9 gene in some mouse models protects against autoimmunity [59].  
In addition to the DNA and DNA containing ICs, RNA and RNA binding proteins, such as 
Sm/RNP, constitute a second major category of autoantigens frequently targeted in systemic 
autoimmune diseases such as systemic lupus erythematosus (SLE). Sm/RNP particles consist of the U1 
RNA bound by Sm and other associated proteins. Recent studies suggest that TLR7 and TLR8 act as 
receptors for single stranded RNA expressed by the viruses. In this context, the ssRNA was found to 
be a particularly effective ligand for TLR7 and TLR8 [56,60]. These observations raised the possibility 
that the interactions between BCR and TLRs that lead to DNA dependent activation of autoreactive B 
cells and DCs, would also apply to TLR7/8 involvement in the activation of B cells by RNA-
associated autoantigens [59]. In agreement with such a concept, TLR7 deficiency ameliorated 
autoimmunity in murine models [59]. Thus, these observations in mouse models are consistent with 
the fact that autoantibodies reactive with DNA or DNA-associated proteins are the earliest and most 
commonly prevalent serological markers of human SLE [47,57].  
5. Role of Dendritic Cells in Central and Peripheral Tolerance  
Interaction of dendritic cells (DCs) with B cells and T cells plays an important role in the regulation 
of immune responses. DCs express a variety of TLRs and respond to TLR stimuli. DCs were found to 
present antigen to both T cells and B cells in a tolerogenic form [61,62]. Immature DCs have been 
shown to inhibit and tolerize T cells in vivo because of the absence of a costimulatory signal, whereas 
maturation of DCs by TLR or CD40 overcomes this inhibitory effect on T cells [62,63]. Recent studies 
suggest that immature bone marrow DCs (iBMDCs) or bone marrow resident DCs, but not mature 
bone marrow DCs or Splenic resident DCs [64], strongly inhibited B cell proliferation and 
differentiation responses induced by TLR ligation. iBMDCs specifically inhibited TLR2, TLR3, and 
TLR4, as well as BCR-induced proliferation, but did not inhibit anti-CD40 or PMA-ionomycin-
induced B cell proliferation [54,65]. Cell-cycle analysis revealed that iBMDCs block B cell 
proliferation by inducing G1-S growth arrest [54]. Similar to the DC-mediated regulation of T cell 
responses, maturation of immature BMDCs with TLR ligands overcame the inhibitory effect of DCs 
on B cells. Many different TLR ligands can mature DCs in either a MyD88-dependent or MyD88-
independent manner [66]. Maturation of immature BMDCs via the MyD88-dependent pathway (LPS, 
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peptidoglycan) or the MyD88-independent pathway [poly(I:C)] had similar effects in overcoming the 
inhibitory effect of iBMDCs on B cells. 
CD22 expression by B cells is critical for the immature BMDC-mediated inhibition of TLR-induced 
B cell proliferation [54]. Interestingly, it has been shown that maturation of BMDCs decreases the 
expression of sialic acid ligands [67], which is consistent with the role of CD22 in DC–B cell 
interaction. It is also possible that the sialic acid binding proteins such as Siglec G, which have been 
shown to be important for B-1 cell responses and for Ag-induced tolerance in B cells could play a role 
in this process [68]. Unstimulated splenic resident DCs were immature as evident by low CD86 and 
class II expression on the surface, compared with LPS mature Spl-RDCs but they did not inhibit  
TLR-induced B cell responses. In contrast, bone marrow resident DCs strongly inhibited TLR induced 
proliferation of B cells from both the bone marrow and the spleen. Although immature BMDCs 
normally are a heterogeneous population of DCs, flow cytometric sorting established that myeloid DCs 
in this population have potent inhibitory effects on B cells [64]. It is of interest to note that  
Kilmon et al. [69] found that myeloid DCs and macrophages, but not plasmacytoid DCs, inhibited 
autoantibody production by self-reactive B cells, but not Ab production by normal B cells. 
In thymus, DCs present self-antigen in the context of their MHC and play a role in the negative 
selection of T cells. Thus, the DCs in the bone marrow might play a similar role in B cell negative 
selection by presenting soluble self-antigens to B cells in membrane bound form in the context of 
CD22/SIGLEC-mediated inhibitory signals. In this context, recently it has been shown that ligation of 
T-independent Ags with sialic acid epitopes induced B-cell tolerance through their ability to crosslink 
SIGLEC family proteins [70,71]. It was proposed that self-antigens that behave like T independent 
Ags may use this pathway for self-tolerance. In support of such an idea, mice doubly deficient for 
CD22 and Siglec G developed autoantibodies and a moderate form of immune complex mediated 
glomerular nephritis [71]. Although the significance of inhibition of TLR responses of bone marrow B 
cells is currently unclear, it must be noted that several endogenous TLR ligands have been identified 
and have been implicated in the breakdown of self-tolerance in several autoimmune models [72,73]. 
Some of the endogenous TLR ligands such as high mobility group box 1 and heat shock proteins have 
their origin in cell death [74], which is known to occur extensively during B cell development. Defects in 
clearance of dead cells have a critical role in the development of autoimmune diseases such as lupus [75]. 
In the periphery, DCs in mucosal areas and epidermal Langerhans cells (sites of extensive cell 
turnover) have anti-inflammatory properties. 
6. Human B Cell Tolerance and Its Impact on Human Autoimmune Diseases 
In the previous sections, we discussed immunological tolerance in B cells based on studies 
performed with transgenic mouse models of B cell tolerance and knockout mice that develop 
autoimmune diseases. In humans, most developing autoreactive B cells in healthy individuals are 
removed at two distinct steps. A vast majority of B cell clones expressing self-reactive B cell receptors 
are eliminated by the central tolerance mechanisms in the bone marrow. A peripheral B cell tolerance 
checkpoint further eliminates autoreactive new emigrant B cells before they enter the mature naive B 
cell compartment. In patients with active autoimmune diseases including rheumatoid arthritis (RA) or 
type 1diabetes (T1D), both the central and peripheral checkpoints are defective [76,77].  
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In autoimmune diseases like multiple sclerosis (MS), RA and to a lesser extent T1D, anti-CD20 
therapy that depletes B cells has shown some efficacy in ameliorating the disease suggesting that the 
deletion of autoreactive B cell clones may reduce disease symptoms in these autoimmune diseases [78]. 
It was reported that a defective peripheral B cell tolerance checkpoint is observed in all three 
autoimmune diseases including MS, T1D, and RA, whereas central B cell tolerance is only impaired in 
two out of three autoimmune diseases (T1D and RA but not in MS) [79]. Hence, defects in the deletion 
of autoreactive B cell clones in the bone marrow seem to be critical for the development of RA and 
T1D, but are dispensable for MS. Genome-wide association studies (GWAS) have demonstrated that 
several susceptibility alleles are shared among many different autoimmune diseases [77]. For example, 
it has been shown that C1858T polymorphism in the PTPN22 gene is associated with high risk T1D 
and RA, but not MS [80]. This PTPN22 mutant blocks both T cell receptor (TCR) and B cell receptor 
(BCR) signaling that regulates central tolerance. Consistent with this hypothesis, it was shown that 
healthy donors carrying the PTPN22 risk allele lack the ability to eliminate autoreactive B cells in the 
bone marrow. This finding is similar to that observed in T1D and RA patients, revealing that this 
susceptibility allele is sufficient to confer the impaired central B cell tolerance associated with these 
autoimmune diseases. Other susceptibility genes associated with T1D and RA, include BLK, LYN, 
PTPN2, and BANK1, all of which affect BCR signaling pathways and may interfere with the removal 
of emerging autoreactive B cells [81]. In contrast, none of these polymorphisms, including the 
PTPN22 variant, are associated with MS, further demonstrating that alterations in B cell intrinsic 
pathways controlling central B cell tolerance may not be necessary for the development of all 
autoimmune diseases. It has been demonstrated that disease-associated polymorphisms in MS mainly 
affect T helper differentiation and B cell-T cell interactions and not B cell intrinsic pathways [79]. In 
contrast to central tolerance mechanisms, the maintenance of the peripheral B cell tolerance checkpoint 
is specifically defective in MS patients, which is postulated to be due to defects in regulatory T cell 
function [79]. 
7. Targeting B Cell Anergy for Therapy  
Several studies demonstrate that the constitutive B-cell receptor (BCR) signaling and response have 
a critical role in the survival and expansion of both B cell lymphoma and the chronic lymphocytic 
leukemia (CLL) clones. CLL patients represent a heterogeneous group with one subset exhibiting an 
indolent disease whereas others progress rapidly necessitating early therapy. It was observed that 
patients with indolent form of CLL are characterized by an expansion of clonal B cells with anergic 
features. In this subset of patients, B cells fail to respond to BCR cross-linking as measured by calcium 
mobilization and protein tyrosine phosphorylation [82,83]. This was characterized as B cell anergy and 
was associated with low levels of surface IgM expression, constitutive activation of ERK1/2 and 
NFATc1 signaling. Chronic BCR triggering promoted CLL cell survival selectively in p-ERK+ve 
subset and treatment with ERK or NF-AT signaling inhibitors specifically induced apoptosis in this 
group of patients. The initial phase of reversal of anergy consists of loss of ERK phosphorylation and 
NF-AT nuclear translocation and restoration of B cell unresponsiveness, reinforcing the notion that the 
anergic signaling favors the chronic survival of leukemic lymphocytes. Thus, it appears that the 
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constitutive signaling observed in B-cell anergy can be efficiently targeted in CLL for therapeutic 
purposes [82]. 
8. Conclusions 
The studies of central B-cell tolerance performed in the last 3 decades in mouse models have given 
us an understanding of forces that shape the murine naive B-cell repertoire. Future challenges will be 
determining the contributions of different forms of tolerance (clonal deletion, anergy, receptor editing 
and BAFF thresholds) to the repertoire of human B cells, and to understanding which of these 
mechanisms is primarily affected in autoimmune diseases. Another challenge will be to increase our 
knowledge of the bone marrow microenvironment to establish whether a specific niche exists for the 
self-antigen presentation to newly generated B cells, and for the processes of negative and positive 
selection. In particular, we will need to define the cytokines and chemoattractants that influence 
immature B-cell selection and their distribution in the marrow environment. Another major challenge 
will be to determine what factors regulate tonic BCR signaling in immature B cells, and particularly 
what defines the signaling threshold that separates negative and positive selection. 
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